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Novelty Statement  
 Assessing diabetes severity is important and could help identify people in need for 
targeted therapies and benchmark healthcare services. 
 This is the first systematic review of measures quantifying type 2 diabetes severity. 
More severe diabetes was associated with greater risks for hospitalisation and 
mortality. Assessing diabetes severity using real-world electronic health records is 
under-researched and underutilised in clinical care. None of the studies compared 
the utility or performance of the developed measures to the currently-used indices, 
mainly glycated haemoglobin (HbA1c). 
 Health records are suitable to assess diabetes severity. Contemporary, actionable, 
and validated disease-specific severity in large diabetes cohorts are needed. 
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Abstract 
 
Aims 
To identify and critically-appraise measures using clinical data to grade the severity of 
type 2 diabetes. 
Methods 
We searched MEDLINE, Embase and PubMed between inception-June 2018. Studies 
reporting on clinical data-based diabetes-specific severity measures in adults with type 
2 diabetes were included. We excluded studies solely reporting other diabetes forms. 
After independent screening, the characteristics of the eligible measures including 
design and severity domains, the clinical utility of developed measures, and the 
relationship between severity levels and health-related outcomes were assessed. 
Results 
We identified 6,798 papers, from which 17 studies reporting 18 severity measures 
(32,314 participants, 17 countries) were included: diabetes severity index (8 studies, 
44%); severity categories (7 studies, 39%); complications' count (2 studies,11%); or 
severity checklist (1 study, 6%). Nearly 89% of the measures included diabetes-related 
complications and/or glycaemic control indicators. Two of the severity measures were 
validated in a separate study population. More severe diabetes was associated with 
increased healthcare costs, poorer cognitive function, and significantly greater risks 
for hospitalisation and mortality. The identified measures differed greatly in terms of 
the included domains. One study reported on the use of a severity measure 
prospectively. 
Conclusions 
Health records are suitable to assess diabetes severity. However, the clinical uptake 
of existing measures is limited. The need to advance this research area is fundamental 
as higher levels of diabetes severity are associated with greater risks for adverse 
outcomes. Diabetes severity assessment could help identify people requiring targeted 
and intensive therapies and provide a major benchmark for efficient healthcare 
services. 
 Keywords: diabetes; severity; type 2 diabetes; electronic health records.
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1. Introduction 
Diabetes mellitus is a long-term metabolic condition associated with an increased risk 
of morbidity and premature mortality, with type 2 diabetes forming over 90% of all 
cases of diabetes [1]. Globally, the management of people with non-communicable 
long term conditions (such as diabetes and heart disease) forms one of the greatest 
challenges facing healthcare systems [2]. The prevalence of diabetes has risen rapidly 
[3, 4] contributing to an estimated 1.6 million deaths worldwide in 2016 [5]. The World 
Health Organization (WHO) estimates that diabetes was the seventh leading cause of 
death in 2016 [5]. The ‘severity’ of clinical conditions can be conceptualised as a 
progression of the underlying disease process, where increasing severity and the 
associated complications lead to increased treatment complexity and greater impact 
on clinical resources [6]. Assessing disease severity in diabetes is important because 
it: i) enables identification of people in greater need for more targeted and intensive 
therapies for risk stratification and to reduce adverse outcomes; ii) could optimise the 
allocation of healthcare resources towards those at greatest risk of harm; and iii) could 
provide a useful means of benchmarking clinical services. Currently, clinicians mainly 
use glycated haemoglobin (HbA1c) levels as a proxy of diabetes severity and for 
management recommendations. However, using HbA1c levels is limited being a 
unidimensional measure, reliance is mainly on last recorded test, the quality of 
recorded data in primary care is questionable despite recent improvements. In 
addition, given the multi-organ involvement in diabetes, a more inclusive proxy for 
diabetes severity is recommended and needed.  
The electronic recording of clinical records has developed substantially since its 
initiation in the 1980s [7] and becoming an important component underpinning clinical 
decision making and systematic care quality improvement [8]. Longitudinal electronic 
health records (EHRs) also enable the study of population health dynamics and form 
a powerful tool to improve the quality and value of health care services[9]. EHRs 
represent real-world data, and are expected to meet minimum standards for data 
quality [10, 11], and are inclusive of all patient groups encountered in routine clinical 
practice that are often excluded in clinical trials (pregnant women, children, the elderly, 
and people with multiple illnesses). Despite the widespread use of EHRs in healthcare 
systems across the world, they are not routinely used in quantifying the severity of 
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long-term conditions such as diabetes. Using such rich medical data to develop 
severity measures for diabetes could represent a practical aid for practitioners, 
supporting clinical management and service-planning.  
Generic severity tools, such as the Charlson Comorbidity Index (CCI) [12] or the Duke 
Severity of Illness (DUSOI) checklist [13] are available but the applicability of such 
global measures of comorbid burden and their relevance specifically to people with 
diabetes, is unclear. Other tools have been developed that incorporate diabetes, such 
as the QRISK2 risk assessment tool (recommended to assess cardiovascular disease 
(CVD) risk in people with type 2 diabetes) [14] but this also provides limited information 
on diabetes severity. Furthermore, existing cardiovascular risk scores perform poorly 
in people with type 2 diabetes.[15] Considering the increasing disease prevalence, 
bespoke tools to assess diabetes severity need to be developed.  
There has been no comprehensive review on the use of health records to develop a 
diabetes-specific severity indices and their predictive values. In this paper we present 
a critical review of studies that have quantified the severity of type 2 diabetes using 
medical data and EHRs. In our review we aimed to: i) describe the design, included 
domains and measured clinical outcomes of identified type 2 diabetes severity 
measures; ii) synthesize the association between type 2 diabetes severity levels and 
health-related outcomes; and iii) identify the likely best-performing severity measure(s) 
or with potentials of influencing clinical interventions based on the importance and 
clinical coherence of included severity domains, utility for primary care, and 
prospective association with clinical outcomes. 
2. Methods 
A protocol for this review is registered in the international prospective register of 
systematic reviews (PROSPERO registration number: CRD42018103147). Our 
review was conducted and reported according to the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) and MOOSE guidelines [16, 17].  
2.1. Data Sources and Searches 
We conducted our search of three main databases from inception to include all 
available studies. We searched MEDLINE (from 1964 to June Week 3, 2018) and 
Embase (from 1974 to June 20, 2018) using the OVID platform, and PubMed (from 
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inception to June 20, 2018). The searches consisted of four core blocks of terms in 
relation to 'diabetes', 'severity', 'grading' and 'stratification'. A combination of keywords 
and MeSH terms were used with appropriate Boolean operators. The detailed search 
strings are listed in Appendix S1. The search strategy was finalised by checking for 
coherence with prior scoping review results from Web of Science and PubMed. 
2.2. Study Selection 
Identified papers were considered eligible if they developed a system for grading the 
severity of type 2 diabetes using a model or algorithm utilising medical record data. 
Severity grading could be based on a simple count of severity domains, pre-defined 
categories of severity or on an assigned numerical score on a severity scale. No 
language or year restrictions were applied. Exclusion criteria included: i) non-research 
articles and examples of grey literature (such as case studies, conference 
proceedings, letters, commentaries or responses to articles); ii) studies not including 
an adult population or only including participants with other types of diabetes (such as 
type 1 diabetes or gestational diabetes); and iii) studies only applying previously 
developed severity indices, unless a substantial modification was conducted. If any 
methodological research was identified among the excluded applied research, it was 
agreed to only include the original work to the review.  
In the first step, one reviewer (S.Z.) screened the references by titles and abstracts to 
assess eligibility and exclude irrelevant papers. The remaining potentially eligible 
papers were then assessed independently by titles and abstracts by two reviewers 
(E.K. and S.Z.) and any discrepancies were resolved by discussion. Cohen's kappa 
was used to measure the agreement between both assessments. Full-text review of 
eligible papers were screened by S.Z. A batch of the eligible papers was reviewed in 
full text by a second reviewer (E.K.). The two reviewers agreed on all decisions 
regarding inclusions and exclusions and therefore just one reviewer continued to 
screen full-text papers. 
 
2.3. Data Extraction and Quality Assessment 
One researcher (S.Z.) extracted relevant information from the final full-text papers in 
pre-designed MS Excel form, including: author(s), year of the study, country, and study 
population demographics (age, gender, duration of diabetes), study design, sample 
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size, variables included to assess severity, design of severity algorithm, the process 
of severity score assignment and score calculation, the outcome(s) associated with 
graded severity (if any), the measure validation (if conducted), and a summary of the 
main findings. Studies to be critically appraised using an appropriate quality 
assessment tool, based on the type of the identified studies. 
2.4. Data synthesis and Analysis 
The primary aim of this review was to identify and describe existing severity measures 
used to assess the severity of type 2 diabetes. The data were narratively synthesised 
and interpreted by: 
1. Describing the characteristics and critically evaluating the design of measures 
used to define the severity of type 2 diabetes and identify the included severity 
domains (predictors that are relevant to the degree of progression of type 2 
diabetes) and reported outcomes.  
2. Synthesising the association between diabetes severity levels and health-
related outcomes. 
3. Identifying the best-performing measure(s) based on performance, the breadth 
of included severity domains and their relevance to primary care. 
 
3. Results 
Our search resulted in 6,798 studies, of which 3,555 duplicates were removed. The 
initial title (and abstract as needed) screening stage of the non-duplicate references 
resulted in the exclusion of 2,893 irrelevant articles. From the remaining 350 papers, 
which were screened independently by two authors (Cohen's Kappa rater agreement 
= 0.95), a further 332 papers were excluded and 18 articles were eligible for full-text 
review.  Five of the 18 eligible papers were independently reviewed in full text by a 
second reviewer.  
One study was excluded [18] after full-text review as a duplication of a previously-
developed diabetes severity measure (already in our review) [19] by updating 
International Classification of Diseases (ICD) codes from ICD-9 to ICD-10. In 
agreement with our eligibility criteria, we retained the paper describing the original 
severity measure. The remaining 17 studies were included in the review. The search 
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and selection stages are illustrated in the PRISMA flowchart chart (Fig. 1). The 
PRISMA checklist is presented in Appendix S2 and the MOOSE checklist in Appendix 
S3.  
No  single quality assessment tool could be used to evaluate the included papers, due 
to their very different designs (e.g. risk prediction models, observational studies or 
other), since such tools include study-type-specific domains. 
3.1. Characteristics of the Included Studies  
Overall, a total of 18 diabetes severity measures reported in 17 studies were 
evaluated. The included studies assessed diabetes severity using various 
approaches, primarily by using either severity categories or a numerical score. Table 
1 presents a summary of the main participants' characteristics for each of the 17 
studies included in the analysis. Of the identified studies, published between 1994 and 
2018, the majority were based in the USA [19-26] while other studies originated from 
China [27], Denmark [28], Germany [29], Italy [30], the Netherlands [31], Spain [26], 
Japan [32], and Australia [33]. One study included participants from 16 countries 
(Australia, Austria, China, Czech Republic, Germany, Denmark, Spain, France, Hong 
Kong, Hungary, Italy, Japan, Korea, Poland, Russia, and the USA) [34]. No studies 
were identified from other countries well-known for their high availability of national 
administrative data, such as the UK. Ten studies were cross-sectional [19, 20, 23, 25, 
28, 31-35]; six were retrospective [21, 22, 24, 26, 29, 30]; and only one reported a 
prospective design by assessing the relationship between longitudinal severity and 
clinical outcome [27]. The study populations consisted mainly of people with type 2 
diabetes only (N=2,889 in 10 studies, 59%), but seven studies (41%) included 
participants with other forms of diabetes in addition to type 2 diabetes (mainly type 1 
diabetes). These seven studies did not describe the distribution of participants by the 
type of diabetes, except in one study where participants with type 1 and type 2 
diabetes formed 12% (N=492) and 88% (N=3,737), respectively [19]. The total 
population from all studies was 32,314 (including participants without diabetes for 
comparison), while the sample size of participants with diabetes was 15,283 (47%) 
and ranged in individual studies between 65 and 4,229 participants. In all, participants 
were aged between 30 and 90 years, of whom 0.0%-71% were women. Middle-aged 
and older people with type 2 diabetes [20], veterans, and first-time heart transplant 
recipients with diabetes were included in some of the eligible studies [22-25].   
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3.2. Characteristics of Diabetes Severity Measures 
Details for the severity measures design, included domains and reported outcomes of 
diabetes severity outcomes across studies are presented in Table 2. 
3.2.1. Severity Measures Design 
Four different designs of diabetes severity measures were identified across the 18 
included measures: i) developing a composite severity index or measure (8 measures, 
44%); ii) using categories of disease severity (7 measures, 39%); iii) using a diabetes 
symptom checklist (1 measure, 6%); and iv) using a simple count of diabetic 
complications (2 measures, 11%). 
i) Composite Severity Index or Measure 
In these studies (8 studies across 11,138 participants), diabetes severity scores were 
either developed as a continuous scale or as a composite severity measure using pre-
determined severity domains [19, 20, 22-26, 32]. Severity scales were based on 
assigning a score (a simple count or a weighted score) to each of the defined severity 
indicators, and from these individual scores, an overall score was calculated. These 
severity measures included clinical indicators including: body mass index (BMI), 
glycated haemoglobin (HbA1c), diabetes duration, type and number of prescribed 
medications, renal function, blood pressure, and diabetes-related microvascular and 
macrovascular complications.  
ii) Categories of Disease Severity 
In studies using severity level categories (7 studies across 2,640 participants), 
participants were categorised as having between two to six levels of severity by pre-
defined diabetes-related criteria [21, 27-30, 33, 35]. The categories were based on 
insulin use, diabetes therapy intensity, the presence of diabetes-related microvascular 
and macrovascular complications, glucose and HbA1c levels, diabetes duration, and 
history of hypoglycaemia. 
iii) Simple Count of Diabetic Complications 
In studies using a count of conditions (2 studies across 5,549 participants), diabetes 
severity was assessed based on a count of diabetes-related complications. In the first 
study, the severity assessment was based on a simple sum of the number of diabetic 
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microvascular and macrovascular complications in 4,229 participants with diabetes 
(type 1 diabetes and type 2 diabetes) from one US geographic region [19]. In the same 
study, the simple count was compared to a composite diabetes severity index (as 
described above) in predicting the risk of hospitalisation, healthcare utilisation and 
mortality. The second study included 1,320 participants with diabetic macular oedema 
enrolled from four studies in 16 countries [34]. The simple count was based on the 
sum of presence or absence of five conditions (pseudophakia, diabetic neuropathy, 
diabetic nephropathy, peripheral vascular disorder, and proteinuria). Each participant 
was assigned a score between 0 (for people without any of these conditions) and 5 
(people with all five conditions). 
iv) Diabetes Symptoms Checklist 
One study used a checklist developed to measure perceived symptom severity and 
assess change over time in 185 participants with type 2 diabetes [31]. The 34-item 
participant-derived clinical checklist categorised diabetes symptom severity into six 
clinical domains including: hyperglycaemic, hypoglycaemic, cardiovascular, 
psychological, neuropathic and ophthalmic. The sample size was however relatively 
small and the checklist was mainly based on participants' perception of diabetes 
severity.  
3.2.2. Severity Domains 
Diabetes-related complications were the most commonly used domains to assess 
diabetes severity, as reported in 11 (61%) of the severity measures [19, 21, 23, 25, 
27, 28, 30-34]. Microvascular complications (diabetic neuropathy, nephropathy and 
retinopathy) and macrovascular events were included. Glycaemic control was the 
second most-commonly included domain, with levels of blood glucose and/or HbA1c 
used in eight (44%) severity measures [21, 22, 26-29, 32, 35]. The complexity of anti-
diabetic treatment domain was also used in four (22%) severity measures and was 
assessed as insulin use and/or the number of prescribed anti-diabetic therapies 
(monotherapy versus drug combinations) [20, 29, 30]. Other domains used to assess 
diabetes severity were diabetes duration [26, 35]; blood pressure levels [22, 28]; the 
presence of renal disease (levels of albuminuria [28] and/or serum creatinine) [19, 22, 
25]; a composite score of: quality of life indicators and counts of comorbidities and 
prescribed medications [20]; demographic variables (age, gender, ethnicity, marital 
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status) [22]; BMI [22]; low density lipoprotein (LDL) levels [22]; a composite history of: 
cerebrovascular and/or cardiovascular disease, severe obesity, and renal failure 
before heart transplantation [24]. 
3.2.3. Measured Outcomes 
The measured outcomes varied form general measures of use of healthcare resources 
and measures of health-related outcomes. In all, the clinical outcomes most-frequently 
related to diabetes severity levels were the risk for hospitalisation (one study),[19] 
healthcare utilisation and/or costs (three studies) [21, 22, 33], and mortality (three 
studies) [19, 24, 33] . Less-frequently, other outcomes assessed in relation to diabetes 
severity in individual studies included haematological changes[32], physical or 
cognitive function [20, 23, 35] , changes in diabetes therapy after bariatric surgery [29]; 
long-term diabetes remission and selection of metabolic surgery [26]; obesity-
associated protein expression [27]; and participant satisfaction [25]. Four studies have 
validated the developed severity measures using a separate dataset or by mapping 
them to clinical outcomes [19, 22, 26, 33]. One study used positive predictive value 
(PPV) to assess the developed type 2 diabetes severity measure (Table 2) [30]. 
3.3. Synthesising the Association between Severity Levels and Health-
Related Outcomes 
The studies that assessed diabetes severity and hospitalisation found that higher 
severity was associated with significantly greater risk for hospitalisation [19]. 
Assessing the relationship between severity of diabetes and healthcare costs and 
adverse events revealed that worsening diabetes was associated with higher mean 
monthly in-patient costs, pharmaceutical and medical costs [21, 22, 33], and 
significantly increased risk for mortality [19, 33]. Severity of diabetes was also related 
to lower patient satisfaction with diabetes care received, cognitive dysfunction and 
significantly higher risks for adverse outcomes - mainly mortality [19-21, 25, 33]. 
Diabetes severity levels were also associated with immunological and haematological 
changes [32]. Table 2 details the association between measured severity and 
outcomes reported in the included studies. The first of the two studies that validated 
the severity measures in a separate population (Spain) reported similar findings to 
those found from the training dataset (USA) [26]. The second study reported 
differences between both datasets in the association between diabetes severity and 
one of two examined outcomes [22]. 
12 
 
3.4. Clinical Performance of Diabetes Severity Measures  
Among the included studies that developed a severity index, the measure reported by 
Young et al. (2008) was potentially the most comprehensive, since it included relevant 
severity domains routinely-recorded in primary care: diabetes-related complications, 
insulin use, and laboratory data and also compared two measures for diabetes 
severity. The study also included a relatively large population of 4,229 participants (the 
largest sample size among all identified studies) from clinics with a large ethnic 
diversity. The developed diabetes complication severity index (DCSI) was validated 
using clinical adverse outcomes and the results indicated that each increasing level of 
the DCSI was associated with a significantly greater risk for hospitalisation (HR: 1.29, 
95% CI: 1.25; 1.32) and mortality (HR: 1.34, 95% CI: 1.28; 1.41) [19]. Additionally, 
when compared to a simple count of diabetes complications, determined also in the 
same study, both measures predicted 2-year mortality well, but the DCSI performed 
significantly better (P<0.0001) as indicated by comparing the area under the curve 
(AUC) of the receiver operating characteristics (ROC) curves of both severity 
measures (0.76 and 0.74). However, the measure did not include non-insulin anti-
diabetic therapies, diabetes duration, and other comorbidities such as hypoglycemia. 
It is noticeable that none of the studies compared the utility or performance of the 
developed severity measures to the currently-used main clinical proxy for diabetes 
severity HbA1c. 
In addition, only few examples of diabetes severity assessments potentially influencing 
clinical care were reported. The first came from a study reporting that diabetes severity 
was significantly associated with cognitive measures and self-care [20]. On that study, 
Gatlin et al. concluded by recommending that it is important for clinicians to consider 
cognitive measures (namely working memory and executive function) when assessing 
self-care in people with diabetes given that the three clinical components (diabetes 
severity, cognitive measures and self-care) appeared to be highly inter-related. In the 
second example, Wang et al. found that fat mass and obesity-associated (FTO) 
protein levels (that positively correlate to waist circumference, BMI and blood glucose 
indices)) increased with increasing type 2 diabetes severity, but significantly declined 
following a 12-week treatment in comparison to before treatment [27].  
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4. Discussion 
4.1. Summary of Main Findings 
Main findings: This systematic review aimed to provide an overview of existing 
measures assessing the severity of type 2 diabetes using clinical data. Our review has 
shown that there has been little development with practical applications of diabetes-
specific severity measures. We found that: i) the most commonly used clinical 
variables for grading type 2 diabetes severity were diabetes-related complications and 
glycaemic control measures; ii) only a few studies considered the type or patterns of 
prescribed (diabetes and non-diabetes) therapies as a proxy for higher severity or 
assessed changes in diabetes severity over time or how therapeutic interventions 
could influence these changes; iii) measured diabetes severity was assessed in 
association with various health-related outcomes, mainly risk for hospitalisation, 
healthcare costs, and death; iv) none of the studies looked at the utility of the severity 
measures in adding prognostic information to the currently-used clinical measures, 
such as HbA1c, and few explicitly presented new actionable severity tools to help 
clinicians target intervention more effectively.  
Studies linking severity with outcome and studies with potential clinical 
applications: In relation to measured outcomes, the studies unsurprisingly showed 
that higher diabetes severity was associated with significantly higher risks for 
hospitalisation and mortality, increased healthcare costs, poorer cognitive function, 
and significantly lower participant satisfaction. However, only few examples of 
diabetes severity measures with potential influence on clinical care were reported. 
 
Strengths and limitations of included studies: The earliest study identified in our 
review was in 1994 while others dated between 2002 and 2018, which indicates an 
increasing interest in this area. The studies were based in 17 countries and collectively 
included a wide range of clinical information relevant to diabetes severity, which could 
inform future measures of diabetes severity. Most of the reported measures and 
scoring approaches considered diabetes-specific severity indicators such as diabetes-
related complications and glycemic level (mainly HbA1c). However, while 
acknowledging the informative nature of the included studies, some severity measures 
missed other clinical data such as diabetes duration, hypoglycemia and CVD, while 
others included domains less applicable to the majority of people with type 2 diabetes 
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such as severe obesity or cerebrovascular accident (CVA). Moreover, some of these 
measures were applied in small cohorts, or in selective cohorts that are rarely 
encountered in non-specialist clinical practice settings. None of the identified 
measures were used prospectively or shown the impact on clinically relevant health-
related outcomes, apart from the aforementioned examples by Gatlin and Wang [20, 
27]. We have emphasised on the only longitudinal study identified in our data 
synthesis, as reporting on the prospective use of diabetes severity measures is an 
important dimension which can impact on clinical outcomes. A major limitation of 
existing severity measures is that they are based on cross-sectional data when clinical 
decisions are taken on implicitly longitudinal, multi-dimensional disease trajectories 
rather than a single measure. Only one of the included studies actively sought the 
patients’ perspectives into the development of disease severity measures. Active 
involvement of patients in future studies is crucial for developing meaningful disease 
severity measures. To sum up, all studies showed early stages of development of 
tools, primarily severity categories and numerical scores. Thus very few studies have 
explored practical implications. 
We focused on the clinical rather than methodological characteristics of the included 
diabetes studies and severity measures. Given the widely different designs of the 
included studies, no consistent quality assessment tool could be applied successfully 
to evaluate the included papers as the tools' specific criteria are not applicable to the 
included heterogeneous studies. 
Challenges and clinical opportunities of developing diabetes severity scores: 
Our review of the literature has shown that there has been little development and few 
practical applications of diabetes-specific severity indices. There is therefore 
considerable scope to work towards advances in refining these indices as reliable and 
practical tools for: i) identifying people by stage of disease to target and expedite 
interventions; ii) monitoring longitudinal trajectories of disease severity or serving as 
an outcome variable (resembling the Patient Reported Outcome Measures (PROMs)), 
for instance assessing the effect of interventions on the changes in severity; iii) 
predicting long term prognosis and underpinning clinical decision support systems for 
different management strategies; iv) inform planning resources for diabetes care in 
national health systems; and v) acting as an actionable tool that can influence 
therapeutic strategies and impact on hard clinical outcomes. 
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Opportunities for future research into diabetes severity scores: The clinical 
manifestations of more severe type 2 diabetes are a consequence of diverse and 
complex pathophysiological processes affecting different organ systems over time, 
making it difficult for a single severity measure to capture this complexity adequately. 
However, further alterations to existing measures would be more appropriate to 
develop severity measures for applications in different areas such as clinical practice 
and research. Many previous studies have relatively failed to capture this complexity 
and disease severity because they have omitted important clinical variables. Despite 
the presence of some diabetes-specific severity indices, we could not identify universal 
agreement around: i) the optimal data needed to create a reliable severity measure; 
ii) which severity measures perform better than others especially in predicting health 
outcomes; iii) or whether the developed models are actionable and would enable self-
care and healthcare professionals to manage diabetes more effectively and improve 
clinical outcomes. Future research could also benefit from patients' and carers' 
perspectives of disease progression in diabetes assessing how patient opinion could 
influence decision making in diabetes care. Future studies developing diabetes 
severity measures should include domains that are routinely-collected in clinical 
practice and well-recorded in EHRs, in order to allow the implementation of these tools 
in practice. 
 
4.2. Limitations and Strengths of This Review 
Our review is limited, firstly, by excluding studies reporting only on other forms of 
diabetes. Although measuring the severity of other forms, mainly type 1 diabetes, 
could be relevant, our focus was on adults with type 2 diabetes in adult population 
because this represents ~90% of all diabetes. Secondly, some of the studies were 
based on people with diabetes managed in specialist facilities and not in routine 
clinical settings, such as veterans and individuals undergoing heart transplantation. 
Therefore, the findings in these selective populations are only likely to be applicable 
in these specific groups and may not generalise well to the wider type 2 diabetes 
population seen mostly in primary care. Thirdly, given the scope of this review and the 
heterogeneous design of included studies, we were not able to critically appraise the 
studies using available and recognised quality assessment tools. Our review has 
several strengths: firstly, to our knowledge this is the first systematic review identifying 
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measures quantifying the severity of type 2 diabetes using medical data, mostly 
collected in clinical settings. Secondly, we used a broad search strategy; inclusion 
criteria had no restriction on year or language. Thirdly, two independent reviewers 
performed the second screening stage. Finally, the review was conducted and 
recorded in accordance to the PRISMA guidelines [16].  
4.3. Implications 
Clinical need and research implications: These findings indicate the potentials of 
disease-specific severity measures derived by clinical data with applications in clinical 
practice in future research. Such measures will allow researchers to better map and 
quantify disease trajectories, in relation to health-related and social outcomes, 
improving clinical trials and observational studies, and eventually allow clinicians to 
use these measures in practice to provide more individualised healthcare. Also, 
severity scores might help improve risk stratification enabling safer delegation of care 
within the clinical team, and provide a more clinically relevant tool than the currently 
used proxy, HbA1c. Although current guidelines for management of type 2 diabetes 
are satisfactory in terms of treatment recommendations, but with an ageing population 
in many countries concerns have been raised regarding the lack of comprehensive 
recommendations that would address the rapidly increasing prevalence of 
multimorbidity (the main component of the disease severity scores). In addition, 
current guidelines, mainly comment on the severity of individual components of 
diabetes (severe hypoglycaemia, severe neuropathy, etc) but not severe diabetes. 
Therefore, a composite score that encompasses all relevant severity domains in 
people with diabetes may be needed. Importantly, the recent consensus report by the 
ADA and the EASD included a recommendation for providing patient-centred care that 
takes multimorbidity into account [36]. Future clinical guidelines for management of 
type 2 diabetes need to provide more comprehensive recommendations that would 
help healthcare professionals to address the rapidly increasing prevalence of 
multimorbidity, a main indicator of increasing disease severity, in people with type 2 
diabetes. Further research is needed as the potential for these developments is 
particularly high in countries where primary care EHRs or national disease registries 
contain comprehensive, clinician-coded data, often supported by financial incentives 
[37, 38]. A more inclusive severity index validated using important clinical outcomes in 
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a large diabetes population cohort, will be welcome. Such a measure would serve as 
an important proxy for health status and in decision making in diabetes care.  
Generalisability: Our findings may have greatest generalizability in countries that 
have access to routinely-collected administrative data, as evidenced by the numerous 
countries in which these studies were conducted and the heterogeneity of the study 
populations. Unsurprisingly, the more recently developed severity measures appear 
to be more promising and better-founded - supported by the rapidly growing availability 
of clinical data and well-characterised diabetes cohorts. This and the quick evolution 
of rich EHRs offer an unprecedented opportunity to use these clinical data to develop 
comprehensive measures assessing diabetes severity and optimal impact in clinical 
care. 
In conclusion, this systematic review highlights that the assessment of type 2 diabetes 
severity using routinely-collected real-world clinical and administrative data is under-
researched and underutilised in clinical care. Ideally, more inclusive type 2 diabetes 
severity measures would be developed using a large collection of high-quality 
longitudinal EHR data from heterogeneous populations or settings. In addition, study 
of the performance of such measures in comparing groups and predicting outcomes 
would be fed back, at scale, to inform the improvement of the measures. The 
existence, development and evolution of high quality EHRs would further improve 
quantification of diabetes severity, which would help identify people with diabetes at 
need for targeted interventions, support clinical decision making, and also expected to 
lead to major clinical and healthcare benefits in the future.  
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Table 1 Descriptive data of the design and study population characteristics of the included studies. * Reporting on the size of diabetes 
population if the study also included participants without diabetes. †Age presented as mean (±SD) unless otherwise stated. 
Study number 
and Author-Year 
Study design 
Study 
population 
size* 
 
Age, years (±SD)† 
Gender 
(women) 
N (%) 
Country 
1. Aminian et al.  
2017 [26] 
Retrospective study 
N=900 
(TD: N=659; 
VD: N=241) 
TD: 51 (±10) 
VD: 52 (±9.0) 
TD: 451 (68) 
VD: 158 (66) 
USA/Spain 
2. Brazier et al. 
2017 [34] 
Cross-sectional study N=1,320 61.7 (±9.7) 580 (43.9) 
Australia, Austria, 
China, Czech 
Republic, Germany, 
Denmark, Spain, 
France, Hong Kong, 
Hungary, Italy, Japan, 
Korea, Poland, 
Russia, and USA 
3. Gatlin et al.  
2015 [20] 
Cross-sectional study N=67 62.9 (±10.9) 37 (55.2) USA 
4. Gibson et al.  
2012 [33] 
Cross-sectional study N=379 48 (±12.5) 220 (58) Australia 
5. Gini et al.  
2016 [30] 
Retrospective study N=300 NA NA Italy 
6 Grootenhuis et 
al. 1994 [31] 
Prospective study 
(cross-sectional data on the relationships between 
diabetes severity and health outcomes were only 
provided) 
N=185 65 (±11) 88 (48) Netherlands 
7. Joish et al. 
2005 [22] 
Retrospective study N=734 65.9 (±10.3) 24 (3) USA 
8. Kerr et al.  
2003 [25] 
Cross-sectional study N=1,314 67 (±11) 26 (2) USA 
9. Linzer et al.  
2005 [23] 
Prospective study (cross-sectional data on the 
diabetes severity tool were only provided) 
N=65 64 (NA) None (0) USA 
10. Munch et al.  
2016 [28] 
Cross-sectional study N=664 
64.4 
(range 19-93) 
280 (42.2) Denmark 
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Study number 
and Author-Year 
Study design 
Study 
population 
size* 
 
Age, years (±SD)† 
Gender 
(women) 
N (%) 
Country 
11. Okano et al.  
2008 [32] 
Cross-sectional study N=142 
Range 30-90 
(NA) 
54 (31.7) Japan 
12. Rosenzweig et 
al. 2002 [21] 
Retrospective study N=508 41.8 (±10) 231 (45.5) USA 
13. Runkel et al.  
2015 [29] 
Retrospective study N=77 48.5 (±8.5) 55 (71.4) Germany 
14. Russo et al.  
2006 [24] 
Retrospective study N=3,687 55.8 (±7.9) 745 (20.2) USA 
15. Schneider et 
al. 2017 [35] 
Cross-sectional study N=602 75 (NA) 381 (63.3) USA 
16. Young et al.  
2008 [19] 
Prospective study (cross-sectional data on the 
diabetes severity tool were only provided) 
N=4,229 63.21 (±13.3) 2,040 (48.2) USA 
17. Wang et al. 
2018 [27] 
Cross-sectional study (12 weeks prospective 
design for the severe diabetes group) 
N= 110 
 Mild severity 
group: 50.3 (±4.2) 
 Severe group: 
52.0 (±3.3) 
 Mild severity group: 
30 (52) 
 Severe group: 25 
(48) 
China 
Abbreviations: NA: not available; SD: standard deviation; TD: training dataset; VD: validation dataset. 
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Table 2 Summary of the severity measures design, included domains and measured health-related outcomes. 
Study 
number 
and 
Author-
Year 
Characteristics 
Association with health-related 
outcomes 
Severity 
measure 
validated 
(Yes/No) 
Severity 
Measure Design 
Severity Domains 
Severity sub-
domains (if 
any) 
Outcomes 
1. Aminian 
et al. 2017 
[26] 
Individualised 
metabolic surgery 
(IMS) score 
Preoperative: 
 Insulin use 
 The number of 
diabetes 
medications 
 Diabetes duration 
 HbA1c level 
- 
Type 2 diabetes remission 
rate and selection between 
two bariatric surgeries 
Remission rates decreased with 
increasing diabetes severity. 
Both surgeries showed significant 
improvements in remission rate 
irrespective of the severity of type 2 
diabetes. 
Yes 
2. Brazier et 
al. 2017 
[34] 
Count of diabetic 
complications 
(score 0 -5) 
Diabetes-related 
complications 
 Pseudophakia  
 Neuropathy 
 Nephropathy 
 PVD 
 Proteinuria 
The relationship between 
visual acuity and 
utility (HRQoL)  
The relationship between visual acuity 
and utilities attenuates with increasing 
diabetes severity. No 
3. Gatlin et 
al. 2015 
[20] 
Modified diabetes 
care profile 
measure 
 Health status 
composite (HSC) 
 The number of 
medications and 
comorbidities 
HSC derived 
from quality of 
life domains 
related to: 
 Physical 
function 
 Pain  
 General  
health 
Association between 
cognitive function, self-care 
and type 2 diabetes severity  
Higher severity was associated with 
cognitive dysfunction, where the working 
memory measure was significantly 
correlated with the diabetes severity 
variables (HSC (r= 0.542, P<0.01); the 
number of prescribed medications (r= -
0.344, P < 0.01); and the number of 
comorbid conditions (r= -0.476, P < 
0.01)). 
No 
4. Gibson et 
al. 2012 
[33] 
Four stages of 
diabetes severity  
 Microvascular 
complications 
 Macrovascular 
complications 
 Retinopathy 
 Neuropathy 
 Nephropathy 
 Cerebrovascul
ar disease 
 Cardiovascular 
disease 
 PVD 
 
 In-patient hospital 
costs 
 Mortality  
Worsening diabetes severity was 
associated with increased hospital costs 
and mortality. 
Yes 
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Study 
number 
and 
Author-
Year 
Characteristics 
Association with health-related 
outcomes 
Severity 
measure 
validated 
(Yes/No) 
Severity 
Measure Design 
Severity Domains 
Severity sub-
domains (if 
any) 
Outcomes 
5. Gini et al.  
2016 [30] 
4-level severity 
categories 
 Insulin therapy 
 Microvascular 
complications 
 Macrovascular 
complications  
 Retinopathy 
 Diabetic foot 
ulcer 
 Lower limb 
amputation 
 Nephropathy 
 Dialysis 
 Cardiovascular 
disease 
 Positive predictive value 
(PPV) for automated 
algorithm 
absence/presence of type 2 
diabetes 
 Agreement between 
automated algorithm and 
GP on severity level 
High PPV (100%) for type 2 diabetes 
detection. High agreement score (Cohen's 
kappa=0.7) between automated algorithm 
and GP assessment.  
Yes 
6. 
Grootenhuis 
et al. 1994 
[31] 
A checklist for 
diabetes severity 
Six dimensions: 
 Hyperglycaemic 
 Hypoglycaemic 
 Cardiovascular 
 Psychological 
 Neuropathic 
 Ophthalmic 
Cardiovascular: 
 Shortness of 
breath 
 Chest pain 
Psychological: 
 Sense of 
fatigue 
 Moodiness 
 
 Measure differences in  
severity between participants 
 Assess severity over time 
 Compare mean severity 
scores in participants with 
different comorbidity status 
and treatment mode 
The patterns of comorbidities and 
prescribed treatments were reportedly 
associated with significant differences in 
the estimated severity scores. The 
checklist was found to be a useful 
diabetes-specific assessment tool for 
clinical studies with ability to detect 
change over time. 
Yes 
7. Joish et 
al. 2005 
[22] 
A diabetes 
severity index 
(DSI) 
10 variables in: 
 Demographic 
measures 
 Glycaemic 
 Renal 
 Cardiovascular 
health status 
 Age, gender, 
ethnicity, 
marital status, 
BMI 
 HbA1c 
 Creatinine 
clearance 
 Systolic and 
diastolic blood 
pressure, LDL 
level. 
Healthcare resource use and 
costs 
Higher diabetes severity was associated 
with higher expenses and healthcare 
utilisation. 
Yes 
8. Kerr et al.  
2003 [25] 
Diabetes related 
components of 
the Total Illness 
 Microvascular 
complications 
 Diabetic eye 
disease 
Participants satisfaction with 
provided care and 
communication  
Individuals with higher diabetes severity 
reported lower satisfaction with subject-
provider communication and overall 
diabetes care 
No 
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Study 
number 
and 
Author-
Year 
Characteristics 
Association with health-related 
outcomes 
Severity 
measure 
validated 
(Yes/No) 
Severity 
Measure Design 
Severity Domains 
Severity sub-
domains (if 
any) 
Outcomes 
Burden Index 
(DM TIBI) 
 Macrovascular 
complications 
 Hypertension 
 Renal 
insufficiency 
 Obesity 
 Diabetic foot 
complication  
 Coronary 
artery disease 
 Congestive 
heart failure 
9. Linzer et 
al. 2005 
[23] 
Diabetes severity 
measure 
(DMSEV) 
 Microvascular 
complications 
 Macrovascular 
complications 
 Eye, foot or 
neuropathic 
symptoms 
 TIA 
 Stroke  
 Myocardial 
infarction 
 Chest pain 
frequency 
 Claudication 
Validation of participant-
based assessment measure 
of type 2 diabetes severity by 
correlating to DMSEV 
measure 
High correlation between the DMSEV and 
all outcomes in the participant -based 
assessment (particularly was highly 
associated with physical function) 
concluding that the participant -based 
assessment questionnaire and DMSEV 
are valid measures of diabetes severity.  
Yes 
10. Munch 
et al. 2016 
[28] 
Three levels of 
severity 
 HbA1c 
 Blood pressure 
 Metabolic 
complications 
 Microvascular 
complications 
 Macrovascular 
complications 
 Insulin 
resistance 
 Glucose levels 
 Retinopathy 
 Diabetic foot 
disease 
 Nephropathy 
 Major 
cardiovascular 
event 
 PVD 
 Measure compliance of 
endocrinologists to risk 
stratification guidance. 
 Investigate the level of 
concordance between 
stratification performed by 
the endocrinologists and 
objective assessments 
High compliance of endocrinologists to 
the Danish guidelines, which recommends 
the stratification of participants into three 
risk stratification levels according to risk 
and complexity of anti-diabetic treatment, 
was reported No 
11. Okano 
et al. 2008 
[32] 
Severity index 
13-point scale 
(scores 0-12) 
 HbA1c 
Diabetes-related 
complications 
Hypertension  
Hyperlipidaemia 
Atherosclerosis 
Retinopathy 
Neuropathy 
Haematological and 
immunological changes 
(counts of white blood cells, 
platelets and lymphocytes) 
Different levels of diabetes severity were 
associated with differences in 
immunological and haematological levels. 
The severity index was positively 
associated with neutrophil counts and 
No 
27 
 
Study 
number 
and 
Author-
Year 
Characteristics 
Association with health-related 
outcomes 
Severity 
measure 
validated 
(Yes/No) 
Severity 
Measure Design 
Severity Domains 
Severity sub-
domains (if 
any) 
Outcomes 
Nephropathy negatively associated with platelet and 
CD19+ lymphocyte counts. 
12. 
Rosenzweig 
et al. 2002 
[21] 
4-level severity 
categories 
 Diabetes-related 
complications 
 Glycaemic control 
 Cardiovascular 
disease 
 Eye disease 
 Neuropathy 
 Renal disease 
 Congestive 
heart failure 
 PVD 
 Total medical and 
pharmaceutical costs 
 Management of 
comorbidities 
Participants with very-high and high risk 
severity levels were found to have 
markedly increased costs compared to 
participants in the lower risk groups. 
Nearly 26% of the total diabetes costs 
were attributed to long term complications 
No 
13. Runkel 
et al. 2015 
[29] 
6-level severity 
categories 
 Anti-diabetic 
treatment 
complexity 
 Glucose levels 
Anti-diabetic 
treatment: 
No therapy 
Diet 
Oral therapy 
Insulin 
Oral and insulin 
Poor control 
despite therapy 
Downgrading of type 2 
diabetes 
(reduction in diabetes 
severity) 
Preoperative diabetes severity 
independently predicted postoperative 
reduction in diabetes severity. Participants 
with lower pre-existing diabetes severity 
and shorter duration of diabetes benefited 
the most from surgery. 
No 
14. Russo 
et al. 2006 
[24] 
Diabetes-related 
complications 
(DRC) 
aggregated 
measure 
History of: 
 Cerebrovascular 
accident (CVA) 
 PVD 
 Severe obesity  
 Pre-heart 
transplantation 
renal failure 
- 
Survival time post heart 
transplantation 
Diabetes severity was related to the risk 
of adverse events post-transplantation. 
Survival after heart transplant was 
inversely related to diabetes severity 
(DRC). 
Median post-transplant survival was 9.3 
years in participants with no DRC; 6.7 
years in participants with one DRC; and 
3.6 years in participants with ≥2 DRCs. 
No 
15. 
Schneider 
et al. 2017 
[35] 
2-level severity 
categories 
 Diabetes duration 
 HbA1c level 
- 
Subclinical brain pathology Participants with more-severe diabetes 
(defined by higher HbA1c or longer 
diabetes duration) had greater burden of 
brain vascular pathology than participants 
with less-severe diabetes. 
No 
28 
 
Study 
number 
and 
Author-
Year 
Characteristics 
Association with health-related 
outcomes 
Severity 
measure 
validated 
(Yes/No) 
Severity 
Measure Design 
Severity Domains 
Severity sub-
domains (if 
any) 
Outcomes 
16. Young 
et al. 2008 
[19] 
 Count of 
diabetic 
complications 
 Severity index 
14-point scale 
(scores 0-13) 
 Diabetes-related 
complications 
 Retinopathy 
 Neuropathy 
 Nephropathy 
 Cerebrovascular 
disease 
 Cardiovascular 
disease 
 PVD 
 Ketoacidosis 
 Hyperosmolar 
and other 
coma 
 Mortality  
 Risk of hospitalisation  
The count of diabetes-related 
complications was associated with higher 
risk for mortality. Compared to 
participants with no complication 
(referent), those with one complication 
had no increased risk; those with three 
complications had a 3-fold higher risk of 
death (adjusted hazard ratio (aHR): 2.7, 
95% CI: 1.8; 4.0), and with ≥5 
complications had a 7-fold higher risk 
(aHR: 7.2, 95% CI: 4.4; 11.7). 
Higher diabetes severity score was 
associated with a higher risk for 
hospitalisation and death. A one-level 
higher diabetes severity score was 
associated with a 1.3-fold higher risk of 
death (95% CI: 1.25; 1.32).  
Yes 
 
17. Wang et 
al. 2018 
[27] 
2-level severity 
categories 
 
 HbA1 
 Diabetes-related 
complications 
 Retinopathy 
 Nephropathy 
Correlation with fat mass and 
obesity-associated (FTO) 
gene expression 
Participants with severe diabetes showed 
significantly higher FTO expression levels 
in comparison to participants with mild 
diabetes. 
Levels of FTO protein were found to be 
significantly associated with waist 
circumference, BMI and blood glucose 
measures. 
No 
Abbreviations: aHR: adjusted hazard ratio; BMI: body mass index; CI: confidence interval; DMSEV: Diabetes severity measure; DRC: diabetes-related 
complications; FTO: fat mass and obesity-associated; GP: general practitioner; HbA1c: glyated haemoglobin; HRQoL: health-related quality of life; LDL: low 
density lipoprotein; PPV: Positive predictive value; PVD: peripheral vascular disease; TIA: transient ischemic attack. 
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Figure legend 
 
Figure 1 PRISMA flow diagram for search and selection strategies for the included 
studies 
